 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Monday
AZILECT: Teva launches Parkinson disease once-daily tablets:
"Israel's Teva Pharmaceuticals said on Monday it had launched Azilect, its once-daily treatment for Parkinson's disease. Azilect was approved by the U.S. Food & Drug Administration in May. Teva Neuroscience, Teva's marketing subsidiary in the United States, will promote the drug in the United States. The new medication, rasagiline tablets sold under the name Azilect, is meant to be taken once a day, as opposed to existing Parkinson's disease (PD) medications taken at times up to five times a day. Azilect is indicated for use as initial monotherapy in early
PD and as adjunct therapy to other medication, levodopa, in moderate-to-advanced disease.
'Azilect provides physicians and people living with PD another treatment option to help control the symptoms of Pakinson's disease,' said Larry Downey, president and chief executive officer of Teva Neuroscience in a statement...."
"Israel's Teva Pharmaceuticals said on Monday it had launched Azilect, its once-daily treatment for Parkinson's disease. Azilect was approved by the U.S. Food & Drug Administration in May. Teva Neuroscience, Teva's marketing subsidiary in the United States, will promote the drug in the United States. The new medication, rasagiline tablets sold under the name Azilect, is meant to be taken once a day, as opposed to existing Parkinson's disease (PD) medications taken at times up to five times a day. Azilect is indicated for use as initial monotherapy in early
PD and as adjunct therapy to other medication, levodopa, in moderate-to-advanced disease.
'Azilect provides physicians and people living with PD another treatment option to help control the symptoms of Pakinson's disease,' said Larry Downey, president and chief executive officer of Teva Neuroscience in a statement...."